Abstract: The present invention relates to nucleic acids, double stranded nucleic acids (dsNAs), and agents for inhibiting expression of STATS. The present invention also includes nanoparticles comprising the nucleic acids, the dsNAs, and/or the agents as well as methods of treating cancer using the nucleic acids, the double stranded nucleic acids (dsNAs), the agents and/or the nanoparticles as disclosed herein. In one embodiment, the target region is within the 3?-UTR region of STATS mRNA.

Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

Abstract: The invention relates to a method of treating a MEK-associated tumor by administering to a subject in need thereof a therapeutically effective amount of a solid form 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

Abstract: A high-temperature and high-pressure simulator for a deep in-situ environment is provided. The simulator includes a high-fidelity sample chamber, where a lower end of the high-fidelity sample chamber is provided with a bottom cylinder. A lower end of the bottom cylinder is provided on a base. A piston rod of the bottom cylinder extends into the high-fidelity sample chamber, and an upper end of the piston rod is provided with a rock sample seat. An upper end of the high-fidelity sample chamber is provided with a rock sample cap. The top of the high-fidelity sample chamber is sealed by an end cap of the high-fidelity sample chamber. An upper end of the end cap of the high-fidelity sample chamber is provided with a multi-section coring drill chamber. The uppermost section of the coring drill chamber is connected to a lift cylinder.

Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.

Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

Abstract: Provided is a speaker box, including: an upper cover, an upper steel sheet; a lower cover, a lower steel sheet; a receiving space, an acoustic unit; and an insert plate arranged in the rear cavity. Upper and lower sides of the insert plate abut against the upper steel sheet and the lower steel sheet, respectively, a position of at least one of the upper steel sheet or the lower steel sheet aligned with the insert plate is provided with a fixing groove passing therethrough, and the insert plate is fixed to at least one of the upper steel sheet or the lower steel sheet through glue injection in the fixing groove. The speaker has characteristics of convenient mounting, good anti-shell vibration effect, and reduced mounting space.

Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.

Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: A medium-voltage grid-connected photovoltaic inverter system includes: a photovoltaic inverter, a medium-voltage transformer, a medium-voltage switch, and an inverter grid-connected controller. A direct current input terminal of the photovoltaic inverter is connected to a direct current bus. A low-voltage side of the medium-voltage transformer is connected to an alternating current output terminal of the photovoltaic inverter. An input terminal of the medium-voltage switch is connected to a high-voltage side of the medium-voltage transformer, and an output terminal of the medium-voltage switch is configured to be connected to a medium-voltage grid. A current sensor is integrated in the medium-voltage switch to detect a grid-connected current of the photovoltaic inverter system and output a current detection signal.

Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.

Abstract: A medium voltage grid-connected photovoltaic inverter system and a photovoltaic power generation system including the same are provided. The medium voltage grid-connected photovoltaic inverter system includes a photovoltaic inverter, a medium voltage transformer, a switchgear, and an inverter grid-connected controller. A low voltage side of the medium voltage transformer is connected to an alternating current output terminal of the photovoltaic inverter. An input terminal of the switchgear is connected to a high voltage side of the medium voltage transformer, and each phase of the switchgear includes two output terminals each for being connected to another switchgear. The inverter grid-connected controller is connected to a controlled terminal of the switchgear, and is configured to control the switchgear to switch off/on, so that the medium voltage grid-connected photovoltaic inverter system is disconnected from or connected to a grid.